MRMS aXelerate for targeted metabolomics profiling of myxobacterial extracts

Significance of the Topic

Myxobacterial secondary metabolome comprises a wide spectrum of bioactive compounds with significant pharmaceutical and biotechnological potential. Profiling these complex extracts requires analytical methods that deliver high sensitivity, ultra-high resolution, and rapid throughput to fully explore genetic biosynthetic capacity and to accelerate natural product discovery.

Objectives and Study Overview

The main goal is to introduce MRMS aXelerate, a workflow integrating flow injection analysis with magnetic resonance mass spectrometry for non-targeted profiling of myxobacterial extracts. Specific objectives include:

• Rapid detection and identification of known secondary metabolites with mass accuracy below 1 ppm.
• Comparison of metabolite production under liquid versus plate cultivation in a high-throughput format.
• Evaluation of method performance in terms of throughput, sensitivity, accuracy, and reproducibility.

Methodology

Myxococcus xanthus DK1622 cultures were grown in liquid medium and on agar plates in biological triplicates. Harvested cells were lyophilized, extracted with methanol, and diluted 1:200. Blank controls were prepared from cultivation media. Two technical replicates per sample were analyzed to assess reproducibility.

Instrumentation Used

• ScimaX MRMS (Bruker Daltonics) with ESI in positive ion mode and quadrupolar phase detection
• Bruker Elute UHPLC for flow injection analysis
• Ultimate 3000 RSLC (Dionex) coupled to maXis 4G UHR-Q-TOF (Bruker Daltonics) as reference LC-MS system
• MetaboScape 4.0 for feature extraction, blank subtraction, library-based annotation, and principal component analysis

Results and Discussion

Throughput and Mass Accuracy:

• FIA-MRMS analysis required only 1.5 minutes per sample vs. 21 minutes for the reference LC-Q-TOF method.
• Key myxobacterial metabolites such as Myxovirescin A were identified with mass errors below 1 ppm.

Sensitivity and Resolution:

• FIA-MRMS detected Myxovirescin H, undetectable by LC-MS, via resolution >400,000 at m/z 648 and adduct assignment within 0.15 ppm error.

Data Reduction and Annotation:

• Automated blank subtraction eliminated ~55% of features arising from complex media background.
• Annotation against MetaboBASE Plant Library, LIPID MAPS, and in-house Myxobase yielded identification of ~14% of filtered features.

Statistical Profiling:

• PCA distinguished liquid culture, plate culture, and blank samples, demonstrating clear clustering of biological and technical replicates.
• Comparative intensity plots for DKxanthene-534, Myxalamid A, Myxovirescin A, and Cittilin A revealed distinct production patterns linked to cultivation conditions.

Benefits and Practical Applications of the Method

• High-throughput screening capability enables rapid analysis of large sample sets in under 2 minutes each.
• Enhanced detection of low-abundance metabolites without chromatographic bias.
• Robust mass accuracy and resolution facilitate confident annotation.
• Automated data processing (blank subtraction, feature extraction, PCA) streamlines decision-making for cultivation optimization and natural product prioritization.

Future Trends and Applications

• Integration with genomic and genome-mining tools to guide targeted metabolite discovery.
• Extension of FIA-MRMS workflows to other microbial, plant, or environmental metabolomic studies requiring high throughput.
• Development of expanded, curated spectral libraries to improve annotation coverage.
• Automation and miniaturization for real-time monitoring and industrial quality control applications.

Conclusion

The MRMS aXelerate workflow on the Bruker scimaX MRMS platform offers a rapid, sensitive, and accurate approach for non-targeted profiling of myxobacterial secondary metabolites. Its ultrafast analysis, combined with effective data reduction and statistical profiling, provides a powerful tool for natural product research and cultivation strategy optimization.

References

1. Krug D, Müller R. Secondary metabolomics: the impact of mass spectrometry-based approaches on the discovery and characterization of microbial natural products. Nat Prod Rep. 2014;31:768–783.
2. Hoffmann T, Krug D, Bozkurt N, et al. Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria. Nat Commun. 2018;9:803.
3. Barsch A, Zurek G, Krug D, Cortina NS, Müller R. Challenges in metabolomics addressed by targeted and untargeted UHR-Q-TOF analysis. Bruker Application Note. 2010.
4. Wenzel SC, Müller R. Myxobacteria—’microbial factories’ for the production of bioactive secondary metabolites. Mol Biosyst. 2009;5:567–574.
5. Hug JJ, Bader CD, Remškar M, Cirnski K, Müller R. Concepts and methods to access novel antibiotics from actinomycetes. Antibiotics. 2018;7:44.
6. Krug D, Zurek G, Schneider B, Bässmann C, Müller R. Analysis of secondary metabolites from myxobacteria using ESI-TOF-MS and PCA. Bruker Application Note. 2007.
7. Fahy E, Subramaniam S, Murphy RC, et al. Update of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res. 2009;50 Suppl:S9–14.